Back to top
more

Menlo Therapeutics Inc. (MNLO)

(Delayed Data from NSDQ)

$6.96 USD

6.96
113,051

-0.04 (-0.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $7.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates

Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%

Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1

Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.

Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses

Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.

Menlo Therapeutics Inc (MNLO) Reports Q1 Loss, Lags Revenue Estimates

Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.

ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.

Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y

Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.

Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.

Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line

Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.

Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).

Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat

Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.

Menlo (MNLO) in Focus: Stock Moves 9.9% Higher

Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study

Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.

Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?

On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

    Menlo Stock Plunges on Phase II Chronic Cough Study Failure

    Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.